Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

PHASE3CompletedINTERVENTIONAL

Enrollment

201

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Zolpidem (SL800750)

Trial Locations (2)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Laval